Consun Pharmaceutical Group Limited provided group earnings guidance for the year ended December 31, 2014. For the year, the company's unaudited consolidated management accounts of the Group, it is expected that the Group would record an increase of not less than 30% in profit attributable to equity shareholders of the Company for the year ended 31 December 2014 as compared with that for the year ended 31 December 2013, which was mainly attributable to the continued growth in sales of the Group's kidney medicines, medical contrast medium and other medicines during the year, and the increase in interest income due to the rise in cash at bank during the year.